• TFBS Bioscience Celebrates 10th Anniversary: Partnering with Taiwan and Japan Companies to Expand Gene Therapy Business Opportunities

  2026-10-14 TFBS Bioscience Celebrates 10th Anniversary: Partnering with Taiwan and Japan Companies to Expand Gene Therapy Business Opportunities TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter "TFBS") marks its 10th anniversary today by announcing four major partnerships and milestones. Its strategic partners include ONODERA GT Pharma (Japan), TOKIWA Bio (Japan), Medigen Vaccine Biologics Corporation (Taiwan), and AMAMUS LIFE TECHNOLOGY (Singapore). Through these cross-border collaborations, TFBS Bioscience will further expand its footprint in the Japanese market, deepen its viral vector manufacturing and testing capabilities, and strengthen Taiwan’s biotechnology supply chain. Learn more

• TFBS Bioscience and TOKIWA Bio Hold Signing Ceremony for Strategic Partnership at "BioJapan 2026"

  2026-10-09 TFBS Bioscience and TOKIWA Bio Hold Signing Ceremony for Strategic Partnership at "BioJapan 2026" TFBS Bioscience, Inc. (TPEX: 6939; Headquarters: New Taipei City, Taiwan; hereinafter "TFBS") and TOKIWA-Bio Inc. (Headquarters: Tsukuba City, Ibaraki Prefecture, Japan; hereinafter "TOKIWA Bio") held a joint signing ceremony at "BioJapan 2026" in Pacifico Yokohama to mark their strategic business partnership in the fields of cell therapy and regenerative medicine.
  Representatives from both companies took the stage to sign the agreement and jointly announced the establishment of a partnership for future business expansion. Learn more

• 【Exhibition & Presentation】Exhibiting and Presenting at BioJapan 2026

  2026-09-24 【Exhibition & Presentation】Exhibiting and Presenting at BioJapan 2026 TFBS Bioscience will be exhibiting at BioJapan 2026 in Yokohama, Japan, from October 7 to October 9, 2026. During the event, in addition to showcasing our latest CDMO and CRO solutions at our booth, we will also participate in the exhibitor presentation hosted by Mitsui Fudosan Co., Ltd. We look forward to connecting with industry partners and attendees at the exhibition. Learn more

• TFBS Bioscience Partners with Medigen Vaccine Biologics to Support Process Development for a Second-Generation Multivalent Enterovirus Vaccine

  2026-08-24 TFBS Bioscience Partners with Medigen Vaccine Biologics to Support Process Development for a Second-Generation Multivalent Enterovirus Vaccine TFBS Bioscience, Inc. (TPEX:6939, Headquarters: New Taipei City, Taiwan; “TFBS”) today announced a new phase of collaboration with Medigen Vaccine Biologics Corporation (TWSE: 6547; “MVC”). Under this collaboration, TFBS will provide contract development and manufacturing organization (CDMO) services for MVC’s second-generation multivalent enterovirus vaccine. Learn more

• TFBS Bioscience and Japan Tissue Engineering Collaborate on Feasibility Study for Commercialization of Regenerative Medicine Products (Autologous Cultured Epidermis, etc.) in Taiwan ～Collaboration under the "FY2026 Healthcare Industry International Expansion Promotion Project Subsidy"～

  2026-08-21 TFBS Bioscience and Japan Tissue Engineering Collaborate on Feasibility Study for Commercialization of Regenerative Medicine Products (Autologous Cultured Epidermis, etc.) in Taiwan ～Collaboration under the "FY2026 Healthcare Industry International Expansion Promotion Project Subsidy"～ TFBS Bioscience, Inc. (Headquarters: New Taipei City, Taiwan; hereinafter "TFBS") and Japan Tissue Engineering Co., Ltd. (Headquarters: Gamagori City, Aichi Prefecture, Japan; hereinafter "J-TEC") have agreed to collaborate on a study regarding a study on the commercialization of J-TEC's regenerative medicine products (such as autologous cultured epidermis) currently marketed in Japan for the Taiwan market. Learn more